Topical issues of diagnosis and treatment of alzheimer’s disease based on modern foreign guidelines
https://doi.org/10.21518/2079-701X-2018-6-33-37
Abstract
The article highlights the issues of pharmacotherapy of Alzheimer’s disease based on the guidelines of the USA National Institute on Aging. It discusses the potential of early diagnosis in preclinical stages of the disease using laboratory and betaamyloid neuroimaging markers, neuronal damage. The role of NMDA receptors antagonist memantine in the regulation of excitotoxicity in dementia of the Alzheimer’s type was determined. The efficacy of memantine approved in the US and Europe for the treatment of moderate and severe Alzheimer’s disease is demonstrated. The paper notes its compatibility with other drugs used in the combination therapy, favourable safety profile and good drug tolerance.
References
1. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheim Dement, 2011, 7(3): 270-279.
2. Davis DG, Schmitt FA, Wekstein DR et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J neuropathol exp neurol, 1999, 58(4): 376-388.
3. Dubois B, Feldman H, Jacova C et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet neurol, 2010, 9(11): 1118-1127.
4. Jack CR Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet neurol, 2010, 9(1): 119-128.
5. Jack CR, Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 2011, 7(3): 257-262.
6. Knopman DS, Parisi JE, Salviati A et al. Neuropathology of cognitively normal elderly. J neuropathol exp neurol, 2003, 62(11): 1087-1095.
7. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 1984, 34(7): 939-944.
8. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association work-groups on diagnostic guidelines for Alzhei mer’s disease. Alzheim dement, 2011, 7(3): 263269.
9. Petersen RC. Mild cognitive impairment. J int med, 2004, 256(3): 183-194.
10. Petersen RC, Smith GE, Waring SC et al. Mild Cognitive Impairment: Clinical Characterization and Outcome. Arch neurol, 1999, 56(3): 303-308.
11. Sheline YI, Morris JC, Snyder AZ et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J neurosci, 2010, 30(50): 17035-17040.
12. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheim dement, 2011, 7(3): 280-292.
13. Vemuri P, Wiste HJ, Weigand SD et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology, 2010, 75(2): 143-151.
14. Gavrilova SI. Guide on geriatric psychiatry. 2nd ed. 2013.
15. Gavrilova SI. Drugs for the treatment of Alzheimer’s disease. In the book Rational Pharmacotherapy in Psychiatric Practice. Ch. 12. Moscow: Litterra, 2012. P. 283.
16. Gavrilova SI, Kolykhalov IV. Use of a test score as an indicator of the efficacy of dementia therapy due to Alzheimer’s disease in clinical practice. Zh. Nevropatologii i Psikhiatrii im. S.S. Korsakova, 2014, 12: 47-52.
17. Gavrilova SI, Kalyn YaB, Safarova TP, Yakovleva OB, Sheshenin VS, Kornilov VV, Shipilova ES. Optimization of antidepressant therapy in the geronto-psychiatric hospital settings. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2015, 6: 24-32.
18. Gavrilova SI. Guide on geriatric psychiatry. Moscow: Pulse, 2014, 383 p.
19. Damulin IV. Vascular dementia: pathogenesis, diagnosis and treatment. Farmateka, 2010, 7: 13-18.
20. Kolykhalov IV. Glutamatergic therapy of Alzheimer’s disease. Farmateka. Spetsialnyy Vypusk. Psikhiatriya/Nevrologiya, 2015: 44-49.
21. Levin OS. Dementia diagnosis and treatment algorithms. М.: MEDPRESS-INFORM, 2011.
22. International Statistical Classification of Diseases and Health Related Problems. The tenth revision (ICD-10). T. 1 (part 1). Geneva: WHO, 1995: 315, 510-551
23. Mikhailova NM. Memantine (Acatinol) in the treatment of vascular dementia (review). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2015, 11: 91-99.
24. Ponomarev VV. Neuro-degenerative diseases. A guide for practitioners. SPb.: Foliant, 2013. 200 p.
25. Odinak MM, Emelin AYu, Dean VS. Advanced capabilities of neuroimaging in the diagnosis of dementia. Psikhiatriya, 2009, 1 (37): 57-61.
26. Odinak MM, Emelin AYu, Lobzin VYu, et al. Cerebral perfusion and cognitive impairment in patients with vascular dementia. Med Akad Zhurn, 2011, 11 (1): 58-64.
27. Uspenskaya OB, Yakhno NN. The impact of memantine on the cognitive function of patients with an amnestic variant for the moderate cognitive impairment syndrome (clinical-psychological and neurochemical study). Nevrologicheskiy Zhurnal, 2009, 14 (3): 37-40.
28. Shprah VV, Suvorova IA. Cognitive impairment and dementia: monograph. Irkutsk: RIO of IGIUV, 2011.
29. Yakhno NN, Zakharov VV. Treatment of mild and moderate cognitive impairment. RMJ, 2007, 15 (10): 797-801.
30. Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementia: guide for practitioners. 3rd ed. Moscow: MEDpress-inform, 2011, 272 p.
Review
For citations:
Nesterova MV. Topical issues of diagnosis and treatment of alzheimer’s disease based on modern foreign guidelines. Meditsinskiy sovet = Medical Council. 2018;(6):33-37. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-33-37
Views:
760
Email this article 